皮肤黑色素瘤患者的微血管密度：最新系统评价与荟萃分析
Microvessel Density in Patients with Cutaneous Melanoma: An Up-to-Date Systematic Review and Meta-Analysis.
作者信息
Perivoliotis Konstantinos, Ntellas Panagiotis, Dadouli Katerina, Koutoukoglou Prodromos, Ioannou Maria, Tepetes Konstantinos
机构信息
Department of Surgery, University Hospital of Larissa, Mezourlo, 41110 Larissa, Greece.
Department of Pathology, University Hospital of Larissa, Mezourlo, 41110 Larissa, Greece.
出版信息
J Skin Cancer. 2017;2017:2049140. doi: 10.1155/2017/2049140. Epub 2017 Dec 26.
BACKGROUND
We conducted a meta-analysis, in order to appraise the effect of microvessel density (MVD) on the survival of patients with cutaneous melanoma.
METHODS
This study was conducted according to the PRISMA guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. A systematic literature search in electronic databases (MEDLINE, Web of Science, and Cochrane Central Register of Controlled Clinical Trials) was performed. Fixed Effects or Random Effects model was used, based on the Cochran test.
RESULTS
In total 9 studies (903 patients) were included. Pooled HR for overall survival (OS) and disease-free survival (DFS) were 2.62 (95% CI: 0.71-9.60, = 0.15) and 2.64 (95% CI: 0.82-8.47, = 0.10), respectively. Odds ratios of overall survival between high and low MVD groups, at 12 (1.45, 95% CI: 0.16-13.24), 36 (2.93, 95% CI: 0.63-13.59), and 60 (4.09, 95% CI: 0.85-19.77) months did not reach statistical significance. Significant superiority of low MVD group, in terms of DFS, at all time intervals (OR: 4.69, < 0.0001; OR: 2.18, = 0.004; OR: 7.46, = 0.01, resp.) was documented.
DISCUSSION
MVD does not affect the HR of OS and DFS. A strong correlation with DFS rates at 12, 36, and 60 months was recorded.
背景
我们进行了一项荟萃分析，以评估微血管密度（MVD）对皮肤黑色素瘤患者生存率的影响。
方法
本研究按照PRISMA指南和Cochrane干预措施系统评价手册进行。在电子数据库（MEDLINE、Web of Science和Cochrane对照临床试验中央注册库）中进行了系统的文献检索。根据Cochran检验，使用固定效应或随机效应模型。
结果
共纳入9项研究（903例患者）。总生存（OS）和无病生存（DFS）的合并风险比分别为2.62（95%CI：0.71 - 9.60，P = 0.15）和2.64（95%CI：0.82 - 8.47，P = 0.10）。高MVD组和低MVD组在12个月（1.45，95%CI：0.16 - 13.24）、36个月（2.93，95%CI：0.63 - 13.59）和60个月（4.09，95%CI：0.85 - 19.77）时的总生存优势比未达到统计学意义。在所有时间间隔内，低MVD组在DFS方面具有显著优势（OR分别为：4.69，P < 0.0001；OR：2.18，P = 0.004；OR：7.46，P = 0.01）。
讨论
MVD不影响OS和DFS的风险比。记录到MVD与12个月、36个月和60个月时的DFS率有很强的相关性。
Zotero 插件